Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of a 12-week candesartan treatment compared with hydrochlorothiazide on insulin sensitivity assessed with hyperinsulinemic euglycemic clamp.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Umeå University
• Collaborators: AstraZeneca; Sahlgrenska University Hospital, Sweden
• Treatments: Candesartan; Candesartan cilexetil; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Male and female 18-70 years old

• Diagnosed hypertension and abdominal obesity (waist circumference greater than or equal to 102 cm (M) or 88 cm (F)

Exclusion Criteria:

• Uncontrolled hypertension

• Treatment with more than two concomitant antihypertensive medications

• Diabetes Mellitus

• Other endocrine disorder

• Severe liver disease

• Severely reduced renal function

• Malignant disease

• Alcohol or drug abuse

• Severe psychiatric illness

• History of stroke, myocardial infarction, unstable angina pectoris, participation in another clinical trial less than two months prior to screening visit

• treatment with anti-obesity drugs

• anti-inflammatory drugs or immunosuppressive drugs